Investigational Site Number :7920003

Izmir TR-35100

1 studies enrolling now · 14 studies all time

What they study most

Allergic Fungal Rhinosinusitis, Asthma, Chronic Graft Versus Host Disease, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colitis Ulcerative, Heart Failure, Hemophilia, Hemophilia A, Plasma Cell Myeloma, Type 2 Diabetes Mellitus

Studies at this site

• A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis — Recruiting now
• Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A — Running, not enrolling
• Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B — Running, not enrolling
• Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study — Running, not enrolling
• A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant — Running, not enrolling
• Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma — Completed
• A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia — Running, not enrolling
• Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) (LIBERTY-AFRS-AI) — Completed
• Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX — Running, not enrolling
• Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma — Running, not enrolling
• A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease. — Running, not enrolling
• Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A — Completed
• Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk — Stopped early